IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01 2024 - 6:00AM
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage
biotechnology company creating and developing engineered IgM
antibodies, today announced that Fred Schwarzer, Chief Executive
Officer, will participate in a fireside chat at the Guggenheim
Healthcare Talks 6th Annual Biotechnology Conference on Thursday,
February 8, 2024, at 2:30 p.m. EST in New York.
A live webcast of the event will be available on the “Events and
Presentations” page in the “Investors” section of the Company’s
website at
https://investor.igmbio.com/news-and-events/events-and-presentations.
A replay of the webcast will be archived on the Company’s website
for 90 days following the presentation.
About IGM Biosciences, Inc.IGM
Biosciences is a clinical-stage biotechnology company
committed to developing and delivering a new class of medicines to
treat patients with cancer and autoimmune and inflammatory
diseases. IGM’s pipeline of clinical and preclinical assets is
based on the IgM antibody, which has 10 binding sites compared to
conventional IgG antibodies with only 2 binding sites. IGM also has
an exclusive worldwide collaboration agreement with Sanofi to
create, develop, manufacture, and commercialize IgM antibody
agonists against oncology and immunology and inflammation targets.
For more information, please visit www.igmbio.com.
Contact:Argot PartnersDavid
Pitts212-600-1902igmbio@argotpartners.com
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From May 2024 to Jun 2024
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Jun 2023 to Jun 2024